Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Nathanson

Showing results (301-310 of 528) with videos related to

Pageof 53
Sort By:
Nature|June 14, 2017
Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistanceSydney M Shaffer, Margaret C Dunagin, Stefan R Torborg, et al.
Cancer Discovery|December 28, 2012
Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancerSusan M Domchek, Jiangbo Tang, Jill Stopfer, et al.
Cell|August 10, 2019
Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint BlockadeJoseph L Benci, Lexus R Johnson, Ruth Choa, et al.
Nature|February 22, 2018
Corrigendum: Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistanceSydney M Shaffer, Margaret C Dunagin, Stefan R Torborg, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|April 4, 2015
Patient feedback and early outcome data with a novel tiered-binned model for multiplex breast cancer susceptibility testingAngela R Bradbury, Linda J Patrick-Miller, Brian L Egleston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2019
Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast CancerAdam A Kraya, Kara N Maxwell, Bradley Wubbenhorst, et al.
American Journal of Human Genetics|March 1, 2003
Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibilityMieke Schutte, Sheila Seal, Rita Barfoot, et al.
Oncotarget|September 23, 2016
Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanomaClemens Krepler, Min Xiao, Minu Samanta, et al.
Oncogene|August 30, 2000
Absence of evidence for a familial breast cancer susceptibility gene at chromosome 8p12-p22N Rahman, M D Teare, S Seal, et al.
HGG Advances|August 26, 2024
Facilitating return of actionable genetic research results from a biobank repository: Participant uptake and utilization of digital interventionsLillian Phung, Elisabeth Wood, Brian Egleston, et al.
Pageof 53

Showing results (301-310 of 528) with videos related to

Sort By:
Pageof 53
Nature|June 14, 2017
Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistanceSydney M Shaffer, Margaret C Dunagin, Stefan R Torborg, et al.
Cancer Discovery|December 28, 2012
Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancerSusan M Domchek, Jiangbo Tang, Jill Stopfer, et al.
Cell|August 10, 2019
Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint BlockadeJoseph L Benci, Lexus R Johnson, Ruth Choa, et al.
Nature|February 22, 2018
Corrigendum: Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistanceSydney M Shaffer, Margaret C Dunagin, Stefan R Torborg, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|April 4, 2015
Patient feedback and early outcome data with a novel tiered-binned model for multiplex breast cancer susceptibility testingAngela R Bradbury, Linda J Patrick-Miller, Brian L Egleston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2019
Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast CancerAdam A Kraya, Kara N Maxwell, Bradley Wubbenhorst, et al.
American Journal of Human Genetics|March 1, 2003
Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibilityMieke Schutte, Sheila Seal, Rita Barfoot, et al.
Oncotarget|September 23, 2016
Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanomaClemens Krepler, Min Xiao, Minu Samanta, et al.
Oncogene|August 30, 2000
Absence of evidence for a familial breast cancer susceptibility gene at chromosome 8p12-p22N Rahman, M D Teare, S Seal, et al.
HGG Advances|August 26, 2024
Facilitating return of actionable genetic research results from a biobank repository: Participant uptake and utilization of digital interventionsLillian Phung, Elisabeth Wood, Brian Egleston, et al.
Pageof 53